Browse > Article
http://dx.doi.org/10.3904/kjm.2013.85.4.385

Data Analysis for Anti-Neoplastic Chemotherapy-Related Adverse Events Reported to the Korean Pharmacovigilance Regional Network  

Lee, Ju-Yeun (College of Pharmacy and Institute of Pharmaceutical Science and Technology)
Jung, Jae-Woo (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine)
Kang, Hye-Ryun (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine)
Lee, Se-Hoon (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine)
Kim, Hyang-Sook (Department of Pharmacy, Seoul National University Hospital, Seoul National University College of Medicine)
Cho, Sang-Heon (Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine)
Publication Information
The Korean Journal of Medicine / v.85, no.4, 2013 , pp. 385-395 More about this Journal
Abstract
Background/Aims: To describe the toxicity profile of anti-neoplastic agents from real clinical settings, we analyzed spontaneously reported adverse events (AEs) using data from the adverse drug reaction (ADR) reporting system of the Korean Food and Drug Administration (KFDA). Methods: Data were extracted from the nationwide spontaneous ADR reporting system of KFDA from July 2009 to December 2010. We extracted and analyzed data related to chemotherapy and identified unlabeled ADR that were not described in the package insert of the products. Results: In total, 5,867 cases of antineoplastic agent-related AE reports were identified after excluding cases for duplication and cases assessed as 'unlikely' and 'unclassifiable', based on expert opinion. Of the patients with AEs, 52.4% were males and the median age was 56 years. In total, 460 AEs (7.8%) from 267 patients were reported as 'serious' AEs. The most common causative anti-cancer drug class was pyrimidine analogs (31.5%), followed by platinum compounds (19.9%), protein kinase inhibitors (10.8%), and taxanes (8.8%). The most common clinical manifestation of AEs was gastrointestinal toxicities (25.5%), followed by skin disorders (25.3%), and generalized reactions (14.3%). In total, 168 cases (2.9%) of unlabeled AEs were identified. Among these, 10 were reported as serious AEs. Conclusions: The most common causative class of antineoplastic agents was that of pyrimidine analogs. Gastrointestinal and dermatological toxicities were the most common clinical chemotherapy-related adverse events. Further investigation and monitoring to evaluate causality associated with unlabeled AEs identified in this analysis are needed.
Keywords
Anti-neoplastic agents; Adverse drug reaction reporting system; Drug toxicity; Neoplasm;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 New Zealand Medicines and Medical Devices Safety Authority. $DBL^{TM}$ Cisplatin injection, prescribing information [Internet]. New Zealand Medicines and Medical Devices Safety Authority, c2012 [cited 2012 Jun 5]. Available from: http://www.medsafe.govt.nz/profs/datasheet/c/ Cisplatinmaynepharmainj.pdf.
2 O'Dwyer JP, Clabby C, Crown J, Barton DE, Hutchinson M. Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology 2005;65:331-332.   DOI   ScienceOn
3 World Health Organization Uppsala Monitoring Center. The WHO adverse reaction terminology [Internet]. Uppsala: World Health Organization Uppsala Monitoring Center, c2012 [cited 2012 Jan 16]. Available from: http://www.umcproducts. com/graphics/3149.pdf.
4 World Health Organization. Collaborating Centre for Drug Statistics Methodology, ATC index with DDDs [Internet]. Oslo: WHO, c2008 [cited 2008 Dec 16]. Available from: http://www.whocc.no/atc_ddd_index.
5 National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.03 [Internet]. Maryland (MD): National Cancer Institute, c2010 [cited 2010 June 20]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
6 Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D, ed. Textbook of Adverse Drug Reactions. New York: Oxford University Press, 1991:18-45.
7 Medina PJ, Shord SS. Cancer treatment and chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a Pathophysiologic Approach. 8th ed. New York: McGraw-Hill, 2011:2191-2228.
8 Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-19.   DOI   ScienceOn
9 Gautier S, Bachelet H, Bordet R, Caron J. The cost of adverse drug reactions. Expert Opin Pharmacother 2003;4: 319-326.   DOI   ScienceOn
10 Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-306.   DOI   ScienceOn
11 Hospira. Methotrexate prescribing information [Internet]. Illinois (IL): Hospira, c2012 [cited 2012 Jun 5]. Available from: http://www.hospira.com/Images/432925_32-91319_1.pdf
12 U.S. National Library of Medicine. Nolvadex prescribing information [Internet]. Maryland (MD): U.S. National Library of Medicine, c2012 [cited 2012 Jun 5]. Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id= 3420.
13 Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011;2011:843019.
14 Ha T, Kwon SJ. Efficacy and safety profile of TS-1 or TS-1/CDDP in patients with advanced gastric cancer. J Korean Gastric Cancer Assoc 2006;6:139-145.   DOI
15 Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7:288-323.   DOI   ScienceOn
16 Gähler A, Hitz F, Hess U, Cerny T. Acute pericarditis and pleural effusion complicating cytarabine chemotherapy. Onkologie 2003;26:348-350.   DOI   ScienceOn
17 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205.   DOI   ScienceOn
18 Hermans C, Straetmans N, Michaux JL, Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol 1997;75:55-57.   DOI
19 Morisaki T, Ohnita K, Takeshima F, et al. A case of sclerosing cholangitis caused by oral chemotherapy with S-1. Nihon Shokakibyo Gakkai Zasshi 2011;108:245-252.
20 Van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-218.   DOI   ScienceOn
21 Lundkvist J, Jönsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 2004;18:275-280.   DOI   ScienceOn
22 Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, Bonhomme C, Bugat R, Montastruc JL. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol 1997;53:19-22.   DOI
23 Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-1117.   DOI   ScienceOn
24 Ladewski LA, Belknap SM, Nebeker JR, et al. Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol 2003;21:3859-3866.   DOI   ScienceOn
25 Lim KH, Shin HT, Sohn HS, et al. Comparison of WHO-ART versus MedDRA, internationally standardized terminology of adverse drug reaction classification. Korean J Clin Pharm 2007;17:46-51.
26 Kubota T. The role of S-1 in the treatment of gastric cancer. Br J Cancer 2008;98:1301-1304.   DOI   ScienceOn
27 Puche Canas E, Luna Del Castillo JD. Adverse drug reactions in patients visiting a general hospital: a meta-analysis of results. An Med Interna 2007;24:574-578.
28 Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol 1998;38:1003-1009.   DOI
29 Ciorciaro C, Hartmann K, Kuhn M. Differences in the relative incidence of adverse drug reactions in relation to age? an evaluation of the spontaneous reporting system of SANZ (Swiss Drug Monitoring Center). Schweiz Med Wochenschr 1998;128:254-258.